NLRP3-IN-2 |
| Katalog-Nr.GC50569 |
NLRP3-IN-2, ein Zwischensubstrat bei der Synthese von Glyburid, hemmt die Bildung des NLRP3-Inflammasoms in Kardiomyozyten und begrenzt die InfarktgrÖße nach myokardialer IschÄmie/Reperfusion bei der Maus, ohne den Glukosestoffwechsel zu beeintrÄchtigen.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 16673-34-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
NLRP3 inflammasome inhibitor. Inhibits formation of NLRP3 inflammasome and IL-1β release in LPS and ATP-stimulated mouse macrophages and cardiomyocytes in vitro. Inhibits NLRP3 activation in mouse acute myocardial infarction and peritonitis models without affecting plasma glucose levels. Glyburide synthetic intermediate.
Marchetti et al (2014) A novel pharmacologic inhibitor of the NLRP3 inflammasome limits myocardial injury after ischemia-reperfusion in the mouse. J.Cardiovasc.Pharmacol. 63 316 PMID:24336017 |Fulp et al (2018) Structural insights of benzenesulfonamide analogues as NLRP3 inflammasome inhibitors: design, synthesis, and biological characterization. J.Med.Chem. 61 5412
Average Rating: 5 (Based on Reviews and 24 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *